An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.